Translating Guidelines and Clinical Trial Data to and ... - Amazon S3

More documents

Recommendations

Info

The Right StuffThe Right DrugThe Right TargetThe Right DiseaseThe Right ContextThe Right ScheduleThe Right DoseThe Right PopulationGaynon P, et al. Br J Haematol. 2005;131(5):579-587.Conclusions• Substantial numbers of young people and adults are cured withcurrent risk-adapted strategies– Various post-induction intensification schemes yield similar outcomeswith similar prognostic factors– Allogeneic BMT remains important for adults– AVN in adolescents and TRM in adults• Relapse remains the major barrier to cure– BMT is not the complete answer to the challenge of relapse• Targeted therapy requires identification of ‘molecularly’homogenous subpopulationsAVN = avascular necrosis; TRM = treatment-related mortality.
Translating Guidelines and Clinical Trial Data to Improved AcuteLymphoblastic Leukemia Management and OutcomesPost-Activity EvaluationTo receive documentation of credit, please print and complete the evaluationand mail or fax it to NACCMELocation of Meeting ____________________________________ Date of Meeting ______________NACCME would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which are rated on a 5-point Likert scale(1 = strongly disagree/poor/very little; 5 = strongly agree/excellent/great deal).1. To what extent were you able to achieve each of the following learning objectives?Outline the current classification system for ALL and the differences in biology and treatmentstrategies between pediatric and adult patients with ALL 1 2 3 4 5Review current evidence for induction, consolidation, maintenance, and transplant strategies in thetreatment of ALL in pediatric and adult patients 1 2 3 4 5Summarize current guideline recommendations for the treatment of both Ph–negative and Ph–positive ALL patients 1 2 3 4 5Outline strategies for the treatment of patients with refractory or relapse ALL1 2 3 4 5Identify emerging treatments and the role of currently available targeted agents in the managementof ALL 1 2 3 4 52. Please rate the faculty in terms of their knowledge and expertise.1 2 3 4 53. Please rate the faculty in terms of their teaching ability.1 2 3 4 54. Please rate the following components relating to this activity:Content 1 2 3 4 5Relevance to your practice 1 2 3 4 5Educational format 1 2 3 4 5Audience-participation portions (eg, Q&A, pre/post-testing) 1 2 3 4 5Handouts and/or other materials supporting the activity 1 2 3 4 5Overall 1 2 3 4 55. How much did you learn as a result of this CE program? 1 2 3 4 5NACCME: 300 Rike Drive, Suite A, Millstone Township, NJ 08535; Phone: 609-371-1137; Fax: 609-371-2733
Page 1 and 2: Translating Guidelinesand Clinical
Page 3 and 4: Distribution of the Common Chromoso
Page 6 and 7: MRD on Day 29 of Induction Predicts
Page 8 and 9: Case 1:13-cv-10020-MLW Document 1 F
Page 11 and 12: CCG-Modified Standard BFMInduction(
Page 13 and 14: EFS During 5 Years ofFollow-Up in A
Page 15 and 16: Maintenance• Daily mercaptopurine
Page 17 and 18: Risk Stratification: Pediatric, T-C
Page 19 and 20: “Targeted Therapy”Ph+ ALL in Ch
Page 21 and 22: Adolescents and Young AdultsInducti
Page 23 and 24: Algorithm for Treatment of BMRelaps
Page 25 and 26: Pre-BMT MRD PredictsPost-BMT Relaps
Page 27 and 28: Clofarabine, Etoposide, and CPM in
Page 29: Toll-Like Receptors• TLR are patt
Page 33 and 34: 17. How often do you intend to use

Translating Guidelines and Clinical Trial Data to and ... - Amazon S3

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?